IFRX · InflaRx N.V.
Market Cap
$225.47M
Shares
147.37M
Volume · Oct 23
117.38K
Avg daily vol (3M)
784.74K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.53
Open$1.55
Day$1.51–1.60
52W close$0.83–2.74
Avg vol 30d644K
Short int12.4M · 8.4% float · 26.6d
Short vol31%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+520.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.8%
Year over year · more shares
Price change (1Y)
+20.5%
Trailing year
Short interest
8.4%
Latest settlement · 26.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−20%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
37%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−27%
trailing
YTD return
+51%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
5 of 62 funds reported for Sep 30 · net +341.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.39% of float · ▲ +2.1% MoM · 26.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
37%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
5 of 62 funds reported for Sep 30 · net +341.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.39% of float · ▲ +2.1% MoM · 26.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 37%
Range high $3
vs 200-day avg -6%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IFRX
this stock
InflaRx N.V.
|
$225.47M | +51.5% | — | — | 8.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +18.0% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.33B | +6.1% | +20.8% | 20.3 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.90B | +587.1% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IFRX | +6.3% | -20.7% | -27.1% | -15.0% | +51.5% |
| SPY | -1.0% | -0.4% | +6.0% | +0.2% | +12.0% |
| vs SPY | +7.3% | -20.3% | -33.2% | -15.2% | +39.5% |